Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 5, Issue 17

September 14 2021

In this Issue

EXCEPTIONAL CASE REPORT
STIMULUS REPORT
SYSTEMATIC REVIEW
CLINICAL TRIALS AND OBSERVATIONS
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION

EXCEPTIONAL CASE REPORT

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance
Clinical Trials & Observations

Justin Anthony Chen,Yanli Hou,Krishna M. Roskin,Daniel A. Arber,Charles D. Bangs,Linda B. Baughn,Athena M. Cherry,Mark D. Ewalt,Andrew Z. Fire,Laure Fresard,Hutton M. Kearney,Stephen B. Montgomery,Robert S. Ohgami,Kathryn E. Pearce,Beth A. Pitel,Jason D. Merker,Jason Gotlib

View Articletitled, Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance

Supplemental data

STIMULUS REPORT

Mechanistic ion channel interactions in red cells of patients with Gárdos channelopathy

Julia Jansen,Min Qiao,Laura Hertz,Xijia Wang,Elisa Fermo,Anna Zaninoni,Raffaella Colombatti,Ingolf Bernhardt,Paola Bianchi,Lars Kaestner

View Articletitled, Mechanistic ion channel interactions in red cells of patients with Gárdos channelopathy

Supplemental data

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms
Clinical Trials & Observations

Miriam Elbracht,Robert Meyer,Kim Kricheldorf,Deniz Gezer,Eggermann Thomas,Beate Betz,Ingo Kurth,Lino L. Teichmann,Tim H. Brümmendorf,Ulrich Germing,Susanne Isfort,Steffen Koschmieder

View Articletitled, Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms

SYSTEMATIC REVIEW

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Abdülkadir Erçalışkan,Duygu Seyhan Erdoğan,Ahmet Emre Eşkazan

View Articletitled, Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

CLINICAL TRIALS AND OBSERVATIONS

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
Clinical Trials & Observations

Isabelle A. van Zeventer,Aniek O. de Graaf,Melanie M. van der Klauw,Edo Vellenga,Bert A. van der Reijden,Jan Jacob Schuringa,Arjan Diepstra,Luca Malcovati,Joop H. Jansen,Gerwin Huls

View Articletitled, Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality

Supplemental data

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Clinical Trials & Observations

Christian Buske,Wojciech Jurczak,Juan-Manuel Sancho,Edvard Zhavrid,Jin Seok Kim,José-Ángel Hernández-Rivas,Aliaksandr Prokharau,Mariana Vasilica,Rajnish Nagarkar,Larry Kwak,Won-Seog Kim,SangJoon Lee,SungHyun Kim,KeumYoung Ahn,Michinori Ogura

View Articletitled, Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Supplemental data

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial
Clinical Trials & Observations

Alex F. Herrera,Catherine Burton,John Radford,Fiona Miall,William Townsend,Armando Santoro,Pier Luigi Zinzani,David Lewis,Camilla Fowst,Satjit Brar,Bo Huang,Aron Thall,Graham P. Collins

View Articletitled, Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Supplemental data

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia
Clinical Trials & Observations

Hasmukh Jain,Manju Sengar,Vasu Babu Goli,Jayashree Thorat,Prashant Tembhare,Dhanlaxmi Shetty,V. N. Avinash Bonda,Lingaraj Nayak,P. G. Subramanian,Bhausaheb Bagal,Nikhil Patkar,Neha Sharma,Himanshi Gupta,Sumeet Gujral

View Articletitled, Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

GENE THERAPY

Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction

Kristopher A. Knight,Christopher W. Coyle,Caelan E. Radford,Ernest T. Parker,Andrew Fedanov,Jordan M. Shields,Fania Szlam,Anatolii Purchel,Michelle Chen,Gabriela Denning,Roman M. Sniecinski,Pete Lollar,H. Trent Spencer,Eric A. Gaucher,Christopher B. Doering

View Articletitled, Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Enhanced self-renewal of human long-term hematopoietic stem cells by a sulfamoyl benzoate derivative targeting p18^INK4C

Yinghui Li,Wenshan Zhang,Yu Zhang,Yahui Ding,Ming Yang,Mei He,Xiaolei Liu,Jiali Gu,Shiqi Xu,Zhiwei Feng,Yafang Li,Jingjing Yin,Huier Gao,Henan Song,Hui Xu,Chaoqun Wang,Qing Ji,Shihui Ma,Wanzhu Yang,Weiping Yuan,Xiang-Qun Xie,Tao Cheng,Yingdai Gao

View Articletitled, Enhanced self-renewal of human long-term hematopoietic stem cells by a sulfamoyl benzoate derivative targeting p18INK4C

Supplemental data

Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation

Rima M. Saliba,Uri Greenbaum,Qing Ma,Samer A. Srour,Yudith Carmazzi,Liang Li,Betul Oran,Michael Moller,Janet Wood,Stefan O. Ciurea,Piyanuch Kongtim,Gabriela Rondon,David Partlow,Dan Li,Katayoun Rezvani,Elizabeth J. Shpall,Kai Cao,Richard E. Champlin,Jun Zou

View Articletitled, Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients
Clinical Trials & Observations

Kent P. Jensen,David A. Hongo,XuHuai Ji,PingPing Zheng,Rahul D. Pawar,Thomas Hsin-Hsu Wu,Stephan Busque,John D. Scandling,Judith A. Shizuru,Robert Lowsky,Asha Shori,Suparna Dutt,Jeffrey Waters,Anirudh Saraswathula,Jeanette Baker,John S. Tamaresis,Philip Lavori,Robert Negrin,Holden Maecker,Edgar G. Engleman,Everett Meyer,Samuel Strober

View Articletitled, Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients

Supplemental data

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
Clinical Trials & Observations

Martina Pennisi,Miriam Sanchez-Escamilla,Jessica R. Flynn,Roni Shouval,Ana Alarcon Tomas,Mari Lynn Silverberg,Connie Batlevi,Renier J. Brentjens,Parastoo B. Dahi,Sean M. Devlin,Claudia Diamonte,Sergio Giralt,Elizabeth F. Halton,Tania Jain,Molly Maloy,Elena Mead,Maria Lia Palomba,Josel Ruiz,Bianca Santomasso,Craig S. Sauter,Michael Scordo,Gunjan L. Shah,Jae H. Park,Lucrecia Yanez San Segundo,Miguel-Angel Perales

View Articletitled, Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Supplemental data

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

Sheila K. Pierson,Sushila Shenoy,Ana B. Oromendia,Alexander M. Gorzewski,Ruth-Anne Langan Pai,Christopher Shield Nabel,Jason R. Ruth,Sophia A. T. Parente,Daniel J. Arenas,Mary Guilfoyle,Manjula Reddy,Michael Weinblatt,Nancy Shadick,Mark Bower,Alessia Dalla Pria,Yasufumi Masaki,Laura Katz,Jason Mezey,Philip Beineke,David Lee,Craig Tendler,Taku Kambayashi,Alexander Fosså,Frits van Rhee,David C. Fajgenbaum

View Articletitled, Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

Supplemental data

IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS

Howard Lin,Brooks P. Scull,Baruch R. Goldberg,Harshal A. Abhyankar,Olive E. Eckstein,Daniel J. Zinn,Joseph Lubega,Jennifer Agrusa,Nader El Mallawaney,Nitya Gulati,Lisa Forbes,Ivan Chinn,Rikhia Chakraborty,Jessica Velasquez,Jordana Goldman,Dalia Bashir,Fong Lam,Eyal Muscal,Michael. M. Henry,Jay N. Greenberg,Stephan Ladisch,Michelle L. Hermiston,Lauren K. Meyer,Michael Jeng,Ahmed Naqvi,Kenneth McClain,Trung Nguyen,Hector Wong,Tsz-Kwong Man,Michael B. Jordan,Carl E. Allen

View Articletitled, IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS

Supplemental data

LYMPHOID NEOPLASIA

IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

Rachel J. Mitchell,Amy A. Kirkwood,Emilio Barretta,Laura Clifton-Hadley,Emma Lawrie,SooWah Lee,Daniel Leongamornlert,David I. Marks,Andrew K. McMillan,Tobias F. Menne,Elli Papaemmanuil,Bela Patel,Pip Patrick,Clare J. Rowntree,Nahid Zareian,Krisztina Zuborne Alapi,Anthony V. Moorman,Adele K. Fielding

View Articletitled, IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

Supplemental data

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa,Vicki L. Gordon,Christopher G. Morris,Briana Wilson,B. Dharmaveer Shetty,Konrad J. Cios,Puja C. Arora,Krista M. Isaac,Shekhar Saha,Timothy P. Bender,Michael E. Williams,Craig A. Portell,Michael J. Weber

View Articletitled, Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Supplemental data

MYELOID NEOPLASIA

KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2

Siyuan Xu,Siqing Wang,Shenghui Xing,Dingdang Yu,Bowen Rong,Hai Gao,Mengyao Sheng,Yun Tan,Yifan Zhang,Xiaojian Sun,Kankan Wang,Kai Xue,Zhennan Shi,Fei Lan

View Articletitled, KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2

Supplemental data

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
Clinical Trials & Observations

Inge van der Werf,Anna Wojtuszkiewicz,Manja Meggendorfer,Stephan Hutter,Constance Baer,Martijn Heymans,Peter J. M. Valk,Wolfgang Kern,Claudia Haferlach,Jeroen J. W. M. Janssen,Gert J. Ossenkoppele,Jacqueline Cloos,Torsten Haferlach

View Articletitled, Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Supplemental data

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Clinical Trials & Observations

Sebastian Stasik,Jan-Niklas Eckardt,Michael Kramer,Christoph Röllig,Alwin Krämer,Sebastian Scholl,Andreas Hochhaus,Martina Crysandt,Tim H. Brümmendorf,Ralph Naumann,Björn Steffen,Volker Kunzmann,Hermann Einsele,Markus Schaich,Andreas Burchert,Andreas Neubauer,Kerstin Schäfer-Eckart,Christoph Schliemann,Stefan Krause,Regina Herbst,Mathias Hänel,Norbert Frickhofen,Richard Noppeney,Ulrich Kaiser,Claudia D. Baldus,Martin Kaufmann,Zdenek Rácil,Uwe Platzbecker,Wolfgang E. Berdel,Jiri Mayer,Hubert Serve,Carsten Müller-Tidow,Gerhard Ehninger,Martin Bornhäuser,Johannes Schetelig,Jan M. Middeke,Christian Thiede,on behalf of the Study Alliance Leukemia (SAL)

View Articletitled, Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Supplemental data

THROMBOSIS AND HEMOSTASIS

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura

Kadri Kangro,Elien Roose,Bérangère S. Joly,György Sinkovits,Tanja Falter,Charis von Auer,Heidi Rossmann,Marienn Reti,Jan Voorberg,Zoltán Prohászka,Bernhard Lämmle,Paul Coppo,Agnès Veyradier,Simon F. De Meyer,Andres Männik,Karen Vanhoorelbeke

View Articletitled, Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura

Supplemental data

High fibrinogen γ′ levels in patient plasma increase clot formation at arterial and venous shear

Fraser L. Macrae,Frauke Swieringa,Johan W. M. Heemskerk,Robert A. S. Ariëns

View Articletitled, High fibrinogen γ′ levels in patient plasma increase clot formation at arterial and venous shear

Supplemental data

Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis

Derek J. B. Kleinveld,Derek D. G. Simons,Charlotte Dekimpe,Shannen J. Deconinck,Pieter H. Sloos,M. Adrie W. Maas,Jesper Kers,Joshua Muia,Karim Brohi,Jan Voorberg,Karen Vanhoorelbeke,Markus W. Hollmann,Nicole P. Juffermans,on behalf of BloodNet

View Articletitled, Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis

Supplemental data

TRANSPLANTATION

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted
Clinical Trials & Observations

Jeremy D. Rubinstein,Xiang Zhu,Thomas Leemhuis,Giang Pham,Lorraine Ray,Sana Emberesh,Sonata Jodele,Shawn Thomas,Jose A. Cancelas,Catherine M. Bollard,Patrick J. Hanley,Michael D. Keller,Olivia Grimley,Diana Clark,Teri Clark,Cecilia S. Lindestam Arlehamn,Alessandro Sette,Stella M. Davies,Adam S. Nelson,Michael S. Grimley,Carolyn Lutzko

View Articletitled, Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted

Supplemental data

Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation
Clinical Trials & Observations

Stéphane Buhler,Helen Baldomero,Sylvie Ferrari-Lacraz,Anne-Claire Mamez,Stavroula Masouridi-Levrat,Dominik Heim,Jörg Halter,Gayathri Nair,Yves Chalandon,Urs Schanz,Tayfun Güngör,Grazia Nicoloso,Jakob R. Passweg,Jean Villard,on behalf of the Swiss Blood Stem Cell Transplantation Group

View Articletitled, Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation

Supplemental data

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation
Clinical Trials & Observations

Marta Peña,Maria Queralt Salas,Alberto Mussetti,Gabriel Moreno-Gonzalez,Anna Bosch,Beatriz Patiño,Laura Jiménez,Meriem Kara,Rocío Parody,Anna Sureda

View Articletitled, Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

Supplemental data

Cover Image

Cover Image

Laser scanning confocal micrograph of a human plasma blood clot with fluorescently labeled fibrin. The plasma for this clot was from a volunteer with a high percentage of the fibrinogen splice variant fibrinogen γ′. An increased percentage of fibrinogen γ′ results in the formation of blood clots with denser fibrin networks that are harder to break down. See the article by Macrae et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Time to revisit reduced-dose radiotherapy for PCNSL?

Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORT

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance Clinical Trials & Observations

STIMULUS REPORT

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms Clinical Trials & Observations

SYSTEMATIC REVIEW

CLINICAL TRIALS AND OBSERVATIONS

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality Clinical Trials & Observations

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study Clinical Trials & Observations

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial Clinical Trials & Observations

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia Clinical Trials & Observations

GENE THERAPY

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients Clinical Trials & Observations

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells Clinical Trials & Observations

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification Clinical Trials & Observations

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia Clinical Trials & Observations

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted Clinical Trials & Observations

Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation Clinical Trials & Observations

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation Clinical Trials & Observations

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance
Clinical Trials & Observations

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms
Clinical Trials & Observations

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
Clinical Trials & Observations

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Clinical Trials & Observations

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial
Clinical Trials & Observations

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia
Clinical Trials & Observations

Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients
Clinical Trials & Observations

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
Clinical Trials & Observations

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
Clinical Trials & Observations

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Clinical Trials & Observations

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted
Clinical Trials & Observations

Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation
Clinical Trials & Observations

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation
Clinical Trials & Observations